DrugId:  1
1. Name:  GW 597599
2. Groups:  Investigational
3. Description:  GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced vomiting; functional dyspepsia; depression and anxiety.
4. Indication:  Investigated for use/treatment in adverse effects (chemotherapy), anxiety disorders, depression, and gastrointestinal diseases and disorders (miscellaneous).
DrugId:  2
1. Name:  CX157
2. Groups:  Investigational
3. Description:  CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
4. Indication:  Anxiety Disorders I,Depression I
DrugId:  3
1. Name:  MN-305
2. Groups:  Investigational
3. Description:  MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
4. Indication:  Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.
DrugId:  4
1. Name:  Cenobamate
2. Groups:  Investigational
3. Description:  YKP-3089 is a novel small molecule that is currently under development as an anxiolytic therapeutic agent. The exact mechanism(s) by which YKP3089 exerts its effects remain under active investigation.
4. Indication:  Investigated for use/treatment in anxiety disorders.
DrugId:  5
1. Name:  ADX10059
2. Groups:  Investigational
3. Description:  ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.
4. Indication:  Investigated for use/treatment in anxiety disorders, gastroesophageal reflux disease (GERD), and migraine and cluster headaches.
DrugId:  6
1. Name:  ND7001
2. Groups:  Investigational
3. Description:  ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity. It is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments.
4. Indication:  Investigated for use/treatment in anxiety disorders and depression.
DrugId:  7
1. Name:  Naluzotan
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in anxiety disorders and depression.
DrugId:  8
1. Name:  Deramciclane
2. Groups:  Investigational
3. Description:  Deramciclane (EGIS-3886) is a non-benzodiazepine-type anxiolytic drug to treat various types of anxiety disorders. Deramciclane is a unique alternative to current anxiolytics on the market because it has a novel chemical structure and target. It acts as an antagonist at the 5-HT2A receptor, as an inverse agonist at the 5-HT2C receptor, and as a GABA reuptake inhibitor.
4. Indication:  Investigated for use/treatment in anxiety disorders.
DrugId:  9
1. Name:  Pyritinol
2. Groups:  Investigational
3. Description:  Pyritinol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
4. Indication:  Not Available
DrugId:  10
1. Name:  Prothipendyl
2. Groups:  Investigational
3. Description:  Prothipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
4. Indication:  Not Available
DrugId:  11
1. Name:  Prazepam
2. Groups:  Approved, Illicit
3. Description:  Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.
4. Indication:  For the treatment of anxiety disorders.
DrugId:  12
1. Name:  Pagoclone
2. Groups:  Investigational
3. Description:  Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures.
4. Indication:  For the potential treatment of panic and anxiety disorders.
DrugId:  13
1. Name:  (1R,2S)-2-Phenylcyclopropanaminium
2. Groups:  Experimental
3. Description:  A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
4. Indication:  Not Available
DrugId:  14
1. Name:  Robalzotan
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in anxiety disorders and depression.
DrugId:  15
1. Name:  Pexacerfont
2. Groups:  Investigational
3. Description:  Pexacerfont has been investigated for the treatment of Alcoholism, Anxiety Disorder, Alcohol Dependence, and Alcohol-Related Disorders.
4. Indication:  Not Available
DrugId:  16
1. Name:  Siramesine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in anxiety disorders.
DrugId:  17
1. Name:  Etifoxine
2. Groups:  Investigational, Withdrawn
3. Description:  Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing. It has similar effects to benzodiazepine drugs, but is structurally distinct and does not bind to the benzodiazepine receptor. It is more effective than lorazepam as an anxiolytic, and has fewer side effects. Etifoxine has been associated with acute liver injury.
4. Indication:  Not Available
DrugId:  18
1. Name:  GSK-356278
2. Groups:  Investigational
3. Description:  Gsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington Disease, Depressive Disorder, Huntingtons Disease, and Depressive Disorder, Major, among others.
4. Indication:  Not Available
DrugId:  19
1. Name:  Ocinaplon
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in anxiety disorders.
DrugId:  20
1. Name:  Meprobamate
2. Groups:  Approved, Illicit
3. Description:  A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
4. Indication:  For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
DrugId:  21
1. Name:  Alprazolam
2. Groups:  Approved, Illicit, Investigational
3. Description:  A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of panic disorders, with or without agoraphobia, and in generalized anxiety disorders. (From AMA Drug Evaluations Annual, 1994, p238)
4. Indication:  For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia.
DrugId:  22
1. Name:  Perazine
2. Groups:  Approved, Investigational
3. Description:  Perazine has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.
4. Indication:  Not Available
DrugId:  23
1. Name:  Benperidol
2. Groups:  Approved, Investigational
3. Description:  Benperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.
4. Indication:  Not Available
DrugId:  24
1. Name:  Opipramol
2. Groups:  Investigational
3. Description:  Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
4. Indication:  Not Available
DrugId:  25
1. Name:  Clotiazepam
2. Groups:  Approved, Illicit
3. Description:  Clotiazepam is a benzodiazepine derivative, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.
4. Indication:  For the treatment of anxiety disorders.
